Medullary Thyroid Cancer Patient’s Assessment of Quality of Life Tools: Results from the QaLM Study | Zendy

Laura Moss | Zendy; Catrin Cox | Zendy; Jonathan Wadsley | Zendy; Kate Newbold | Zendy; Mark W. J. Strachan | Zendy; Maralyn Druce | Zendy; Neil Tolley | Zendy; Kathryn Graham | Zendy; Sarah Jefferies | Zendy; Lydia Fresco | Zendy; S. Sivabalasingham | Zendy; Alistair Balfour | Zendy; Chris Hurt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Medullary Thyroid Cancer Patient’s Assessment of Quality of Life Tools: Results from the QaLM Study

Author(s) -

Laura Moss,

Catrin Cox,

Jonathan Wadsley,

Kate Newbold,

Mark W. J. Strachan,

Maralyn Druce,

Neil Tolley,

Kathryn Graham,

Sarah Jefferies,

Lydia Fresco,

S. Sivabalasingham,

Alistair Balfour,

Chris Hurt

Publication year - 2020

Publication title -

european thyroid journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.23

H-Index - 10

eISSN - 2235-0802

pISSN - 2235-0640

DOI - 10.1159/000509227

Subject(s) - medicine , medullary thyroid cancer , thyroid cancer , quality of life (healthcare) , disease , thyroid , cancer , stage (stratigraphy) , oncology , pediatrics , nursing , paleontology , biology

Medullary thyroid cancer (MTC) is a neuroendocrine tumour and a rare variant of thyroid cancer with different aetiology, presentation and treatment to differentiated thyroid cancer. Currently available thyroid cancer-specific quality of life (QoL) tools focus on issues and treatments more relevant to patients with differentiated thyroid cancer and therefore may not address issues specific to a MTC diagnosis and cancer journey.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research